Transcription of Supplementary Appendix
{{id}} {{{paragraph}}}
Supplementary AppendixThis Appendix has been provided by the authors to give readers additional information about their to: Zinman B, Wanner C, Lachin JM, et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med 2015;373:2117-28. DOI: (PDF updated November 30, 2015.) Supplementary Appendix Supplement to: Zinman B, Wanner C, Lachin J, et al. Empagliflozin, Cardiovascular Outcomes and Mortality in Type 2 Diabetes. N Engl J Med. Table of Contents Section A. List of investigators .. 2 Section B. Trial committees and independent statistical center ..14 Section C. Definition of high risk of cardiovascular events.
Supplementary Appendix This appendix has been provided by the authors to give readers additional information about their work. Supplement to: Zinman B, …
Domain:
Source:
Link to this page:
Please notify us if you found a problem with this document:
{{id}} {{{paragraph}}}